Brief: Cytodyn Inc Files Modified IND And Protocol For Phase 2 Clinical Trial For Treatment Of Patients With Coronavirus With Leronlimab (Pro 140)
16/03/2020 10:32
March 16 (Reuters) - Cytodyn Inc CYDY.PK :
* CYTODYN INC - FILES MODIFIED IND AND PROTOCOL FOR PHASE 2
CLINICAL TRIAL FOR TREATMENT OF PATIENTS WITH CORONAVIRUS WITH
LERONLIMAB (PRO 140)
Source text for Eikon: ID:nGNX9WYdt7
Further company coverage: CYDY.PK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cytodyn
See all newsBrief: Cytodyn Appoints Robert E. Hoffman As Chief Executive Officer
Brief: Cytodyn Closes $17.5 Million Financing To Fund Continued Development Of Leronlimab
Brief: CytoDyn Inc Files For Offering Of Up To 120 Million Shares Of Common Stock By Selling Stockholder - SEC Filing
Brief: Cytodyn Files For Mixed Shelf Of Up To $100 Million - SEC Filing
Brief: CytoDyn Announces First Patient Dosed in Phase II Oncology Trial in Colorectal Cancer